Physician profile
Tamara Johnson
NPI 1952792392
$4,257.67
in general payments reported to CMS, 2019-2025
21 companies · $426 in 2025
The $426 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $742 · 2020: $490 · 2021: $665 · 2022: $525 · 2023: $523 · 2024: $887 · 2025: $426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,791 · Travel and Lodging: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,790.74 |
| Travel and Lodging | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,639.08 | 2019-2025 | |
| Allergan, INC. | $558.54 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $459.30 | 2019-2024 | Xarelto |
| Gilead Sciences, INC. | $391.98 | 2019-2025 | Veklury |
| Viiv Healthcare Company | $383.22 | 2019-2025 | Dovato, Rukobia |
| Melinta Therapeutics, LLC | $128.10 | 2019-2025 | Kimyrsa, Rezzayo, Vabomere |
| Astellas Pharma US INC | $99.00 | 2019 | |
| Janssen Products, Lp | $99.00 | 2021 | |
| Janssen Biotech, INC. | $97.85 | 2020-2021 | |
| Pfizer INC. | $75.41 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $61.35 | 2024 | Nuzyra |
| Glaxosmithkline, LLC. | $52.13 | 2021-2022 | |
| Insmed, INC. | $38.65 | 2019-2020 | |
| Aimmune Therapeutics, INC. | $35.78 | 2024-2025 | Vowst |
| Organogenesis INC. | $32.85 | 2021-2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $26.02 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $17.38 | 2024 | Lifevest |
| Tetraphase Pharmaceuticals, INC. | $16.36 | 2019 | |
| Merck Sharp & Dohme LLC | $15.92 | 2020 | |
| Astrazeneca Pharmaceuticals Lp | $15.42 | 2019 | |
| Ferring Pharmaceuticals INC. | $14.33 | 2023 | Rebyota |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamara Johnson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.